title: Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region.
abstract: Rabbit immune sera raised against synthetic peptides of the HTLV-II envelope gp46 region were examined for HTLV-II neutralization ability by HTLV-vesicular stomatitis virus (VSV) pseudotype assay and syncytium inhibition assay. HTLV-II neutralization activity was detected in the sera against HTLV-II Env gp46, 80-103 but not in those to HTLV-II Env gp46, 171-196. Three rabbits immunized with the synthetic peptide of HTLV-II Env gp46, 80-103 and three non-immunized rabbits were challenged with intravenous inoculation of an HTLV-II-producing human cell line (MOT, 1 x 10(7) cells). The non-immunized rabbits showed seroconversion for HTLV-II after 2 weeks and maintained persistent infection but the immunized rabbits were protected from HTLV-II infection. Nested or repeated polymerase chain reaction revealed the presence of HTLV-II provirus sequences in the non-immunized rabbits but not in the immunized rabbits. These results suggest that peptide vaccination with a synthetic peptide corresponding to the HTLV-II neutralization region is useful for preventing HTLV-II infection.
authors.affiliation: Second Department of Pathology, Okayama University Medical School, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kariya
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
authors.forename: H
authors.initials: H
authors.lastname: Hoshino
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: T R
authors.initials: TR
authors.lastname: Koirala
authors.forename: N
authors.initials: N
authors.lastname: Ohara
authors.forename: K
authors.initials: K
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Akagi
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D017931:DNA Primers; D004279:DNA, Viral / Q000032:analysis; D015480:Deltaretrovirus Antibodies / Q000097:blood / Q000276:immunology; D004195:Disease Models, Animal; D015686:Gene Products, env / Q000138:chemical synthesis / Q000276:immunology*; D015726:Giant Cells; D015491:HTLV-II Infections / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D015367:Human T-lymphotropic virus 2 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011817:Rabbits; D015682:Retroviridae Proteins, Oncogenic / Q000138:chemical synthesis / Q000276:immunology*; D017386:Sequence Homology, Amino Acid; D014614:Vaccines, Synthetic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*; D054299:env Gene Products, Human Immunodeficiency Virus
chemical_list: D017931:DNA Primers; D004279:DNA, Viral; D015480:Deltaretrovirus Antibodies; D015686:Gene Products, env; D015682:Retroviridae Proteins, Oncogenic; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D054299:env Gene Products, Human Immunodeficiency Virus; C069568:gp46 protein, Human immunodeficiency virus 2